Helius Medical Technologies - Home


Call us: +1 877-564-0008


Stock Quote - HSDT

*Delayed quote courtesy of Google.

NEWTOWN, Pa., July 31, 2017 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX:HSM) (TSX:HSM.WT) (OTCQB:HSDT)  ("Helius" or the "Company"), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announce the formation of a newly constituted Scientific Advisory Board including Dr. Gopal Chopra to serve as Chairman.

“I am delighted we have recruited a good friend and respected colleague to take on this important responsibility,” said outgoing chair, Dr. Jonathan Sackier. “Dr. Chopra’s work as a neurosurgeon and entrepreneur position him ideally to assume the mantle of Chairman of our Scientific Advisory Board (SAB). Gopal and I, together with the company leadership, have reconfigured our SAB to guide Helius towards commercialization of our investigational and disruptive PoNS™ Therapy. We want to thank Dr. Ron Alterman, Dr. Jennifer Sweet, Dr. Jim Surmeier, Dr. Reggie Edgerton, Major General Gale Pollock (ret) and Dr. Rick Celebrini for their service. I can now focus as Chief Medical Officer on the other exciting projects we are working on as we move towards bringing PoNS™ Therapy to the numerous patients who may benefit. Our excellent team is growing and Gopal enhances our reach into the medical community.”

“Helius has an extraordinarily simple non-invasive way of tapping into the brain’s ability to create new connections after injury or disease,” said Gopal Chopra, M.D. “With the world of neuroscience exploring the future of connecting the brain with computers and electronic interfaces, the team we are bringing to Helius will explore the frontiers of neuroplasticity and the previously untreatable world of brain injury. It will be a pleasure to work alongside this world-class team of neuroscience experts."

Remaining SAB Members Include:

Dr. Jonathan Sackier, Chief Medical Officer, Helius Medical Technologies

Carl Hauser, M.D., Director of Trauma and attending surgeon at Beth Israel Deaconess Hospital; visiting professor of Surgery at Harvard Medical School

Scott Parazynski, M.D., Former NASA astronaut, inventor and leader in the medical device and medical research fields

Catherine Cho, M.D., Clinical Associate Professor, Department of Neurology at New York University Langone

New SAB Members Include:

Gopal Chopra, M.D., Co-founder and managing partner of TCG, neurosurgeon and serial entrepreneur in medtech and healthtech

Ann M. Graybiel, Ph.D., Institute Professor at MIT, The McGovern Institute of Brain Research. Her research focuses on the regions of the forebrain that influence movement, mood and motivation, and how these regions function in health and disease.

Raj K. Narayan, M.D., FACS, Professor and Chairman of the Department of Neurosurgery at Hofstra Northwell School of Medicine and Director of the Northwell Neuroscience Institute. He is recognized internationally for his work on traumatic brain injury.

Ali Rezai, M.D. is the Director of the Neurological Institute and Associate Dean of Neuroscience at The Ohio State University Wexner Medical Center.

For full biographies of Helius’ Scientific Advisory Board members, please visit: http://heliusmedical.com/index.php/about/advisory-board 

About PoNS™ Therapy

The Portable Neuromodulation Stimulator (PoNS) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS Therapy combines the use of the device with physical or cognitive therapy and is currently being evaluated in a multicenter clinical trial for the treatment of chronic balance deficits for subjects with mild to moderate Traumatic Brain Injury.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. For more information, please visit www.heliusmedical.com.

Cautionary Disclaimer Statement:

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws (“forward-looking statements”).

All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding the expected use of proceeds from the Private Placement and the business objectives of the Company.

Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the necessity of conducting successful clinical testing to establish safety and effectiveness of the PoNS Therapy for human performance improvement, the requirement for regulatory approval for marketing for human performance improvement prior to the Company’s ability to commercialize the PoNS Therapy for such indications, and other risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company’s business are more fully discussed in the Company’s Transition Report on Form 10-KT for the period ended December 31, 2016, which has been filed with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com, and the Company’s other filings with the SEC and Canadian securities regulators from time to time.

The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.